Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 10/20 | 0.35 |
| ▸ | HTR1B | P28222 | 10/20 | 0.34 |
| ▸ | HTR1A | P08908 | 5/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 3/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3770009 | 0.87 | HTR1D (0.36) | HTR1DHTR1BHTR1AHTR2AHTR2C | |
| SCHEMBL3767892 | 0.81 | HTR1D (0.31) | HTR1DHTR1B | |
| SCHEMBL3764867 | 0.79 | HTR1D (0.36) | HTR1DHTR1BHTR1AMTNR1BHTR2A | |
| SCHEMBL4533872 | 0.75 | HTR1D (0.31) | HTR1DHTR1B | |
| SCHEMBL3772837 | 0.73 | CAPN1 (0.34) | HTR1DHTR1BHTR1A | |
| SCHEMBL3770818 | 0.71 | HTR1D (0.30) | HTR1DHTR1B | |
| SCHEMBL78477 | 0.69 | HTR1D (0.66) | HTR1DHTR1BHTR1AHTR2AHTR2C | |
| SCHEMBL3465851 | 0.68 | — | — | |
| SCHEMBL4756458 | 0.68 | — | — | |
| SCHEMBL4757234 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851634-B2 | 5-amino 4-hydroxy-7-(1H-indolmethyl)-8-methylnonamide derivatives as renin inhibitors for the treatment of hypertension | NOVARTIS AG (CH) | 2010-12-14 | — | — | US | disclosed |
| US-20080280895-A1 | 5-Amino-4-Hydroxy-7-(1H-Indolmethyl)-8-Methylnonamide Derivatives as Renin Inhibitors for the Treatment of Hypertension | NOVARTIS AG (CH) | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280895-A1 | 5-Amino-4-Hydroxy-7-(1H-Indolmethyl)-8-Methylnonamide Derivatives as Renin Inhibitors for the Treatment of Hypertension | REN, AGTR1, AGTR2 | HTR1D 197/4885HTR1B 213/4885HTR1A 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.